New Jersey Vioxx® Trial: Merck Wins a Causation Claim, Enters Next Phase in Second Case

WHITEHOUSE STATION, N.J., April  5, 2006 - A jury in Atlantic County Superior Court in Atlantic City, New Jersey today rejected a claim by one of two plaintiffs that VIOXX contributed to his heart attack.  The jury also awarded a compensatory award to a second plaintiff.  The trial is continuing into the punitive phase for the second plaintiff.  Merck will present evidence it believes shows that the Company submitted to the U.S. Food and Drug Administration all relevant and material information concerning VIOXX.  Merck will make further statements after the jury completes its deliberations after this phase of the trial.

About Merck
Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first.  Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs.  The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them.  Merck also publishes unbiased health information as a not-for-profit service.  For more information, visit www.merck.com.

Forward-Looking Statement
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements.  The forward-looking statements may include statements regarding product development, product potential or financial performance.  No forward-looking statement can be guaranteed, and actual results may differ materially from those projected.  Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.  Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2005, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.

top